hero

Portfolio

The quality and scale of Royalty Pharma’s portfolio of pharmaceutical royalties is unparalleled in the industry. Starting in 1996, we have meticulously acquired royalty interests in many of the industry’s leading drugs by sales that address serious unmet medical needs and improve the lives of patients around the world.

Portfolio

Cabometyx

Exelixis / Ipsen / Takeda

ADVANCED RENAL CELL CARCINOMA
HEPATOCELLULAR CARCINOMA

2021

APPROVED

gsk

Oxlumo

Alnylam

PRIMARY HYPEROXALURIA TYPE 1

2021

APPROVED

Dicerna

Seltorexant

Johnson-Johnson

MDD WITH INSOMNIA SYMPTOMS

2021

PRE-APPROVAL

Minerva

Orladeyo

Biocryst

HEREDITARY ANGIODEMA

2020

APPROVED

Biocryst

BCX9930

Biocryst

PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

2020

PRE-APPROVAL

Biocryst

Kalydeco

Vertex

CYCSTIC FIBROSIS

2020|2014

APPROVED|APPROVED

Cystic Fibrosis Foundation

Orkambi

Vertex

CYSTIC FIBROSIS

2020|2014

APPROVED|PRE-APPROVAL

Cystic Fibrosis Foundation

Symdeko

Vertex

CYSTIC FIBROSIS

2020|2014

APPROVED|PRE-APPROVAL

Cystic Fibrosis Foundation

Trikafta

Vertex

CYCSTIC FIBROSIS

2020|2014

APPROVED|PRE-APPROVAL

Cystic Fibrosis Foundation

Nurtec ODT

Biohaven

MIGRAINE

2020|2018

APPROVED|PRE-APPROVAL

Biohaven

Evrysdi

Roche

SPINAL MUSCULAR STROPHY

2020

PRE-APPROVAL

PTC Therapeutics

Idhifa

Celgen

RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

2020

APPROVED

Agios

Prevymis

Merck

CYTOMEGALOVIRUS INFECTION

2020

APPROVED

AiCuris

Entyvio

Takeda

ULCERATIVE COLITIS CROHN'S DISEASE

2020

APPROVED

Massachusetts General Hospital

Tazverik

Epizyme

EPITHELIOD SARCOMA FOLLICULAR LYMPHOMA

2019

PRE-APPROVAL

Eisai Global

Crysvita

Kyowa Kirin

X-LINKED HYPOPHOSPHATEMIA

2019

APPROVED

Ultragenyx

Emgality

Eli Lilly

MIGRAINE

2019

APPROVED

Arteaus

Promacta

Novartis

CHRONIC ITP

2019

APPROVED

 

Trodelvy

Gilead

BREAST CANCER

2018

PRE-APPROVAL

Immunomedics

Tysabri

Biogen

MULTIPLE SCLEROSIS

2017

APPROVED

Perrigo

Xtandi

astellas Pfizer

PROSTATE CANCER

2016

APPROVED

UCLA

Bosulif

Pfizer

CHRONIC MYELOID LEUKEMIA

2014

PRE-APPROVAL

Pfizer

Soliqua

Sanofi

DIABETES

2014

PRE-APPROVAL

 

Imbruvica

AbbVie / Johnson-Johnson

CHRONIC LYMPHOCYTIC LEUKEMIA MANTLE CELL LYMPHOMA

2013

PRE-APPROVAL

Quest Diagnostics

Tecfidera

Biogen

MULTIPLE SCLEROSIS

2012

PRE-APPROVAL

 

Cimzia

UCB Pharma

RHEUMATOID ARTHRITIS

2012

APPROVED

Nektar

Mircera

Roche

CHRONIC KIDNEY DISEASE

2012

APPROVED

Nektar

Galvus / Eucreas

Novartis

DIABETES

2011

APPROVED

Astellas

Januvia / Janumet XR

Merck

DIABETES

2011

APPROVED

Astellas

Nesina

Takeda

DIABETES

2011

APPROVED

Astellas

Tradjenta

Boehringer Ingelheim / Lilly

DIABETES

2011

APPROVED

Astellas

Onglyza / Kombiglyze XR

AstraZeneca

DIABETES

2011

APPROVED

Astellas

Lexiscan

Astellas

PHARMACOLOGICAL STRESS AGENT FOR MYOCARDIAL PERFUSION IMAGING

2011

APPROVED

 

Lumizyme / Myozyme

Sanofi

POMPE DISEASE

2011

APPROVED

 

Letairis / Volibris

Gilead

PULMONARY ARTERIAL HYPERTENSION

2009

APPROVED

 

Rotateq

Merck / Sanofi

ROTAVIRUS VACCINE

2008

APPROVED

Children's Hospital of Philadelphia

Remicade

Johnson-Johnson / Merck / Mitsubishi Tanabe Pharma

RHEUMATOID ARTHRITIS ULCERATIVE COLITIS

2007

APPROVED

NYU

Lyrica

Pfizer

NEUROPATHIC PAIN

2007

APPROVED

Northwestern

Prezista

Johnson-Johnson

HIV

2007

APPROVED

 

Humira

AbbVie

RHEUMATOID ARTHRITIS ULCERATIVE COLITIS

2006

APPROVED

AstraZeneca

Atripla

Bristol-Myers Squibb

HIV

2005

APPROVED

Emory

Complera

Gilead

HIV

2005

APPROVED

Emory

Descovy

Gilead

HIV

2005

APPROVED

Emory

Genvoya

Gilead

HIV

2005

APPROVED

Emory

Emtriva

Gilead

HIV

2005

APPROVED

Emory

Truvada

Gilead

HIV

2005

APPROVED

Emory

Odefsey

Gilead

HIV

2005

APPROVED

Emory

Stribild

Gilead

HIV

2005

APPROVED

Emory

Thalomid

Celgene

MULTIPLE MYELOMA

2001

APPROVED

EntreMed

Tobi

Novartis

CYSTIC FIBROSIS

1999

APPROVED

 

PRODUCT MARKETER TOP INDICATIONS YEAR OF ACQUISITION STATUS AT ACQUISITION ROYALTY SELLER